PRECIGEN, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
PRECIGEN, INC. (PGEN) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of $60.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2025-03-19
- PRECIGEN, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was $60.00K, a 94.59% decline from fiscal 2023.
- PRECIGEN, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was $1.11M, a 108.07% increase from fiscal 2022.
- PRECIGEN, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2022 was $533.00K.
- PRECIGEN, INC. effective income tax rate reconciliation, other adjustments, amount for fiscal 2021 was -$46.00K.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $60.00K 10-K · filed 2025-03-19 | |
| 2023-12-31 | $1.11M 10-K · filed 2025-03-19 | |
| 2022-12-31 | $533.00K 10-K · filed 2025-03-19 | |
| 2021-12-31 | -$46.00K 10-K · filed 2024-03-19 | |
| 2020-12-31 | -$306.00K 10-K · filed 2023-03-06 | |
| 2019-12-31 | -$72.00K 10-K · filed 2022-03-01 | |
| 2018-12-31 | -$3.52M 10-K · filed 2021-03-01 | -$486.00K 10-K · filed 2019-03-01 |
| 2017-12-31 | -$189.00K 10-K · filed 2020-03-02 | -$64.00K 10-K · filed 2018-03-01 |
| 2016-12-31 | $1.49M 10-K · filed 2019-03-01 | |
| 2015-12-31 | -$98.00K 10-K · filed 2018-03-01 | |
| 2014-12-31 | $1.50M 10-K · filed 2017-03-01 | $0.00 10-K · filed 2015-03-02 |
| 2013-12-31 | $1.32M 10-K · filed 2016-02-29 | -$2.48M 10-K · filed 2014-03-31 |
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |